Clinical Trial Results:
"Estudio de fase IIIB, multicéntrico, abierto, de 12 meses de duración para evaluar la seguridad, tolerabilidad y eficacia de ranibizumab (0.3 mg) en pacientes con neovascularización coroidea subfoveal secundaria a la degeneración macular asociada a la edad"
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration
Summary
|
|
EudraCT number |
2005-005921-73 |
Trial protocol |
ES GB PT IT BE DE HU NL FI |
Global completion date |
18 Apr 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
31 Mar 2016
|
First version publication date |
31 Mar 2016
|
Other versions |
|
Summary report(s) |
CRFB002A2303_CT_gov_results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.